Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5526_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
31.08.2026
Размер:
29 Мб
Скачать
29 Migraine-Like Aura Attributed toCerebral Amyloid Angiopathy (CAA)
275
visual and sensory symptoms—occurring in the absence of signicant headache— was consistent with migraine-like aura attributed to CAA, a known but underrecog­nized manifestation of the disease.

29.4 Clinical Presentation

A retrospective study conducted between 2012 and 2018 investigated migraine prevalence and symptomatology in patients with familial CAA (D-CAA), correlat­ing migraine history with ICH onset, ICH location, and cSS presence on MRI.Among 86 carriers, 48 (56%) had a positive migraine history, mostly among women (60%). According to ICHD-3 criteria, 39 (45%) had denite migraine, with all migraine sufferers experiencing aura. Specically:
• 42% had only visual auras.
• 12% experienced additional sensory aura symptoms.
• 5% had additional aphasia.
• 24% had typical aura without headache, with 14% reporting this as their only
migraine attack type.
The age of onset for migraine with aura showed two peaks: one before the third decade and another after the fourth decade. The prevalence of migraine in D-CAA was signicantly higher for both men (51%) and women (59%) compared to the general Dutch population (lifetime prevalence: 13% in men and 33% in women). Notably, all D-CAA patients with migraine experienced visual aura. Single aura symptoms lasting more than 60min were observed in 23% of patients. While pro­longed aura is common in the general population, it is concerning in D-CAA carri­ers, as it indicates acute ICH in 55% of cases [4].
Migraine-like aura has been reported in rare monogenic cerebrovascular syn­dromes and may serve as an early hallmark or isolated symptom. Examples include cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoen­cephalopathy, as well as retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. These ndings suggest a link between migraine and microvascular changes during the early stages of angiopathies [5].
Numerous monogenic disorders may manifest with aura, occasionally presenting as “true” migraine with aura, fullling ICHD-3 criteria. These disorders affect vari­ous biological pathways, including ion channels, vascular proteins, and mitochon­drial metabolism, contributing to increased susceptibility to spreading depolarization—an underlying mechanism of aura. Therefore, a distinct clinical classication from typical migraine is warranted for patients with hereditary condi­tions, necessitating tailored management strategies [4, 5].
276
M. E. Nobre

29.5 Diagnosis

Neurological symptoms, such as cerebral hemorrhagic manifestations, transient focal neurological episodes, memory clinic indicators, headache, or migraine-like aura, must be considered [2, 4].
Imaging tests, including magnetic resonance imaging (MRI) and computed tomography (CT) scans, are essential. Predominantly involving the small cortical and leptomeningeal vessels, amyloid-β CAA can be identied in life by character­istic hemorrhagic structural imaging markers on blood-sensitive MRI sequences, namely cortical supercial siderosis and lobar cerebral microbleeds. These hemor­rhagic imaging markers, along with symptomatic bleeding events, such as paren­chymal ICH and acute convexity subarachnoid hemorrhage, form the basis of the diagnostic Boston criteria [24].
Other nonhemorrhagic imaging features, such as cerebral atrophy, white matter hyperintensities, and MRI-visible perivascular spaces in the centrum semi-ovale (CSO-PVS), are also commonly observed in sporadic CAA.Although these are not necessarily specic to CAA, white matter hyperintensities in a “multispot” pattern and CSO-PVS have been included in the most recent Boston criteria (Version 2.0). There are also CT-based diagnostic criteria for CAA (the Edinburgh criteria); how­ever, these require knowledge of the epsilon 4 allele (APOE ε4) genotype for com­plete application. Validation of using the imaging components alone is ongoing, but early suggestions indicate that they do possess diagnostic accuracy [24].
As MRI is more widely used for the clinical assessment of various neurological conditions, an increasing number of individuals are identied as having imaging features of CAA, which can be incidental or unexpected ndings. Although clinical context is essential for determining their signicance, in younger patients present­ing with ICH, cognitive symptoms, or transient focal neurological episodes, the presence of these markers may indicate certain rare but essential causes of CAA that warrant specic and focused investigation, with implications for patients and their families [24].
Amyloid-PET imaging can also be helpful. However, it is essential to recognize that tracers can bind to other amyloids and are therefore not specic for amyloid-β [2].
Cerebrospinal uid (CSF) measurement of amyloid-β markers can be valu­able, although validated thresholds for the clinical diagnosis of CAA have not yet been established. The presence of CSF amyloid-β1–42 levels or a CSF amyloid-β1–42/1–40 ratio consistent with Alzheimer’s disease would support a diagnosis of cerebral beta-amyloidosis [24].
Genetic testing may also be necessary in the context of CAA.Hereditary forms associated with mutations in genes like APP (amyloid precursor protein) or PSEN1/ PSEN2 (presenilin 1/2) could be identied through genetic testing, especially if there is a family history suggesting genetic predisposition to CAA or early-onset Alzheimer’s disease. Thus, genetic testing can help inform diagnosis and manage­ment for affected individuals [35].
29 Migraine-Like Aura Attributed toCerebral Amyloid Angiopathy (CAA)
Primary migraines can often present with aura symptoms (visual, sensory, or speech-related) and may occur independently of CAA.A review of the differential diagnosis of late-onset aura (LOA) indicates that TIAs, seizures, subarachnoid hem­orrhage, arteriovenous malformation, dural arteriovenous stula, patent foramen ovale, posterior circulation embolism, internal carotid artery dissection, vertebral artery dissection, carotid artery stenosis, moyamoya disease, brain tumors, and other rare disorders can also mimic migraine aura, in addition to CAA.Therefore, the diagnosis of late-life migraine accompaniments should be made by exclusion through appropriate investigations [3, 4, 6].
277

29.6 Treatment

The treatment of migraine-like aura associated with cerebral amyloid angiopathy (CAA) primarily aims to manage symptoms and reduce the risk of complications, as there is no specic therapy targeting the aura itself. Symptomatic treatment may include standard migraine medications if the headache follows the aura, although the aura itself typically does not respond to these treatments. Preventive strategies focus on lifestyle modications such as maintaining proper hydration, ensuring regular sleep patterns, and avoiding known migraine triggers like stress or certain foods. It is also essential to control vascular risk factors—particularly hypertension, hyperlipidemia, and diabetes—as these can exacerbate the underlying pathology and increase the risk of cerebral hemorrhage or ischemic events.
In patients with CAA, the use of anticoagulants is generally avoided due to the heightened risk of intracerebral bleeding, unless there is a compelling indication. Education of the patient and family is a key part of the management strategy, empha­sizing awareness of potential neurologic symptoms and the importance of promptly reporting any new changes. Ongoing monitoring through regular neurologic follow­ up is crucial to evaluate disease progression and to adjust the treatment plan as needed.
Ultimately, management should be individualized based on the frequency and severity of aura episodes, the presence of associated headaches, and the patient’s overall health status. A collaborative, multidisciplinary approach allows for a per­sonalized care plan that addresses both the symptoms of migraine-like aura and the complexities of cerebral amyloid angiopathy.

29.7 Conclusion

Migraine with aura is an important, often inaugural symptom of CAA.Aura attacks lasting 60min may signal acute ICH in CAA.Migraine with aura may be regarded as an early marker of disease in hereditary CAA, potentially preceding the occur­rence of symptomatic ICH by several years [4]. Although mostly benign, late-onset
278
M. E. Nobre
aura (LOA) must be differentiated from secondary causes [6]. Blood-sensitive mag­netic resonance imaging sequences are the best tools for the early detection of underlying pathology; therefore, treatment with antiplatelet or anticoagulant drugs should be avoided, as these may increase the risk of hemorrhage [6].
Management of patients with CAA and migraine-like symptoms focuses on treating underlying risk factors, monitoring for complications, and sometimes employing standard migraine treatments if warranted. However, caution is advised, as specic migraine treatments may increase the risk of hemorrhage in patients with CAA [6, 7].

References

1. Vinters HV.Cerebral amyloid angiopathy: a critical review. Stroke. 1987;18(2):311–24. https://
doi.org/10.1161/01.str.18.2.311. PMID: 3551211.
2. Banerjee G, Collinge J, Fox NC, Lashley T, Mead S, Schott JM, Werring DJ, Ryan NS.Clinical
considerations in early-onset cerebral amyloid angiopathy. Brain. 2023;146(10):3991–4014.
https://doi.org/10.1093/brain/awad193.
3. Smith EE, Charidimou A, Ayata C, Werring DJ, Greenberg SM.Cerebral amyloid angiopathy-
related transient focal neurologic episodes. Neurology. 2021;97(5):231–8. https://doi.
org/10.1212/WNL.0000000000012234. Epub 2021 May 20. PMID: 34016709; PMCID:
PMC8356377.
4. Koemans EA, Voigt S, Rasing I, Van Etten ES, Van Zwet EW, Van Walderveen MAA,
Wermer MJH, Terwindt GM.Migraine with aura as early disease marker in hereditary Dutch-
type cerebral amyloid angiopathy. Stroke. 2020;51(4):1094–9. https://doi.org/10.1161/
STROKEAHA.119.028170.
5. Pensato U, Demchuk AM, Dreier JP, Brennan KC, Sacco S, Romoli M.Aura phenomenon: a
proposal for an etiology-based clinical classication. J Headache Pain. 2025;26(9):1–9. https://
doi.org/10.1186/s10194- 024- 01943- 8.
6. Samanci B, Coban O, Baykan B.Late onset aura may herald cerebral amyloid angiopathy: a
case report. Cephalalgia. 2016;36(10):998–1001. https://doi.org/10.1177/0333102415620253.
Epub 2015 Nov 26. PMID: 26611682.
7. Paterson RW, Uchino K, Emsley HC, Pullicino P. Recurrent stereotyped episodes in cere-
bral amyloid angiopathy: response to migraine prophylaxis in two patients. Cerebrovasc
Dis Extra. 2013;3(1):81–4. https://doi.org/10.1159/000347114. PMID: 23741226; PMCID:
PMC3670647.
Chapter 30
Headache Attributed toPituitary Apoplexy
CarolinaMartins , JesuínoAlbino , JulianaAndrade , andMarceloValença

30.1 Introduction

Apoplexy derives from a Greek root and means “a sudden blow.” In medicine, it is used to characterize the sudden onset of a set of signals and symptoms (hence, a syndrome), usually related to the infarction of hemorrhage of an organ or structure. When no anatomical ndings accompany such a syndrome, the term functional apo­plexy is applied.
Pituitary apoplexy, therefore, is a term used to describe a sudden constellation of signs and symptoms related to endocrinological, visual, oculomotor, or meningeal symptoms resulting from vascular changes (infarction, hemorrhage or both) within the sellar content. Apoplexy happens in the context of adenomas, Rathke cysts and several other pituitary lesions, including normal pituitary glands in especial condi­tions (pregnancy, puerperal period) [1]. Nevertheless, it is commonly seen in the setting of an undiagnosed pituitary adenoma [2].
The incidence of apoplexy in pituitary adenomas when considering clinical and surgical or histopathological evidence is 2–7% [3]. This combination of factors must be differentiated from the ndings of hemorrhagic infarction in lesions har­bored by asymptomatic patients which reach up to 25% [3]. This differentiation is paramount because the latter does not conform with a diagnosis of pituitary
C. Martins (*) · J. Andrade · M. Valença Department of Neuropsychiatry, Federal University of Pernambuco (UFPE), Recife, Brazil e-mail: maria.cmlima@ufpe.br
J. Albino Neurocirurgia Assistência e Ensino (NAE), Recife, Brazil
Switzerland AG 2026 D. Uludüz et al. (eds.), Rare Causes of Headache Disorders, Headache,
https://doi.org/10.1007/978-3-032-10242-3_30
279© The Author(s), under exclusive license to Springer Nature
280
C. Martins et al.
apoplexy. Pituitary apoplexy was rst described as a syndrome by Pearce Bailey, in 1898 [3], it received this denomination in 1950, by Brougham etal. [4].
Lesions of the sellar and parasellar regions are a common nding in the general population and their incidental ndings on cadaveric and health volunteer imaging studies vary from 1.7% to 27% [5]. On the other hand, headache as a presenting complaint among patients with pituitary lesions range from 33% to 73%, consis­tently higher than the prevalence of headaches in the general population, meaning that sellar lesions do cause headache—and in fact this is often the primary reason leading to the diagnosis [5]. Because scant data exist on the specic improvement of headache after surgical treatment of sellar/parasellar lesions, it remains challeng­ing to indicate surgical resection in patients harboring these lesions—and no other sign or symptom.
Among sellar lesions, adenomas are the most frequent, occurring in 20% of the general population [6], from childhood to the elderly, and most of them being incidental and asymptomatic (at the most 5% of adenomas are symptom­atic) [5]. Adenomas can be classied by (a) size—as microadenomas (less 10mm), macroadenomas (more than 10mm), and giant macroadenomas (more than 40mm in greatest dimension), (b) hormonal production—as functional and non-functional, (c) histology, or (d) biologic behavior [6]. Among functional adenomas, prolactinomas are the most frequent. Prolactinomas comprise 30% of all adenomas, while nonfunctional adenomas correspond to another 25–30% [6].
This being said, apoplexy, therefore, occurs when a sellar structure—usually a pituitary adenoma—undergoes hemorrhage, infarction, or both. Most cases affect males (twice as likely to present with apoplexy) [7], during fth or sixth decade of life, often on previously unidentied non-functional adenomas or prolactinomas.
Because apoplexy differs signicantly from the incidental nding of a sellar/ parasellar lesion during the investigation of a headache patient, the surgical consid­erations made above do not apply. It is fundamental to understand that apoplexy results in a life-threatening situation with pressing goals that take precedence over (but fortunately overlapping) with the relief of the headache.

30.2 Clinical Case

A 37-year-old male was transferred to a tertiary, neurovascular unit hours after having presented himself at his district health unit, with a sudden and severe headache, vomiting, and decrease in visual acuity. Although his admission occurred two months into the ofcial coronavirus disease 2019 (COVID-19) pan­demic period in our region—and at a time when no specic diagnostic tests were available—suspected patients were in small numbers, community spread low, and it was still possible to keep infected patients segregated within a part of our health
30 Headache Attributed toPituitary Apoplexy
281
network. The headache woke him out of sleep, and he experienced sudden vomit­ing at the installation of the complaints. Neurological examination at the emer­gency department showed Glasgow Coma Scale of 12 out of 15. He was restless and anxious, complaining of a throbbing headache. He was not cushingoid, acro­megalic, or eunuchoid and no gynecomastia or galactorrhea was present. Unable to help with the bedside visual acuity test, the patient kept repeating that he could not see well, especially with his left eye. There was a sluggish light reex bilater­ally and a questionable nuchal rigidity. A subarachnoid hemorrhage was the ini­tial diagnostic assumption, as no previous medical history of a sellar lesion existed. A computed tomography (CT) scan (Fig.30.1A–D), however, showed an enlarged sella and an intrasellar lesion that extended to the suprasellar space and protruded towards the cavernous sinuses, particularly on the left. A bright, thin halo on the top of the lesion suggested focal subarachnoid intracranial hemor­rhage. The patient was admitted to the intensive care unit (ICU) with the diagno­sis of apoplectic, previously undiagnosed sellar lesion and routine preoperative exams as well as hormonal serum prole were collected. An endovenous (EV) bolus of hydrocortisone 500mg was administered before surgery, while awaiting the results of the hormonal prole. Five hours after admission he was taken to the operating room (OR) and a microsurgical transsphenoidal surgery with endo­scopic assistance performed. During surgery, the bony sellar oor was found thinned and eroded, with a tense sellar dura prolapsing towards the sphenoidal sinus. Dural opening initially relieved a liquied, reddish bloody content and fur­ther material was collected under the surgical microscope with transsphenoidal microsurgical curettes. The endoscope was introduced to explore the cavity at the end of the procedure and further laterally displaced material removed, except on the right side, where the pituitary gland seemed to have been displaced. The sella oor was closed using a bony fragment reserved from the sphenoidal rostrum dur­ing the approach, supported by Gelfoam cubes. The surgical procedure was undertaken under 150minutes. At the immediate postop period, the patient indi­cated relief both of his headache and visual disturbances. The same-day postop CT scan (Fig.30.1E–H), 17hours after the admission CT, showed adequate sellar decompression. Preop serum prole disclosed only mild elevation of serum pro­lactin, compatible with infundibular compression by a non-secreting pituitary adenoma, later conrmed by histopathology. The postop period was uneventful, during which rst line, EV, analgesic drugs, were administered, when needed, and were enough to control his headache. Oral hydrocortisone was swiftly tapered off while monitoring the urinary density and output. The patient was able to perform a campimetry on the third postop day. He was discharged on the fourth postop day, after repetition of the hormonal prole and having the rst endocrinologic outpatient consultation scheduled within a fortnight. The rst neurosurgical out­patient follow-up, scheduled in four weeks’ time included evaluation of postop magnetic resonance imaging (MRI) and comparative campimetry.
282
C. Martins et al.
A
B
C
E
F
G
D
Fig. 30.1 (AD) Emergency room (ER) admission, non-contrast CT scans on axial (AC) and sagittal (D) planes. A predominantly hyperdense sellar lesion extended to the suprasellar area (a). A hyperdense halo is seen around the edges of the lesion. The oor of the III ventricle and infun­dibulum cannot be seen on the sagittal view, but the subarachnoid cisterns are opened (b), and the sulci and gyri can be delineated, suggesting an absence of signicant elevation of global intracra­nial pressure. The oor of the sella did not—at rst—seem thinned, but it was found during sur­gery to be eroded and breached, with a tense, bulging sellar dura protruding into the sphenoid sinus (c) suggesting increase intrasellar pressure. (EH). Postoperative, non-enhanced CT scan obtained 17hours after admission. Adequate debulking of the lesion has been achieved, but for a small remnant on the right of the sella that seemed particularly stuck during surgery. With decompression of the sella, the oor of the III ventricle and infundibulum (d) could then be seen (H).
H
30 Headache Attributed toPituitary Apoplexy
283

30.3 Clinical Presentation

Typically, signs and symptoms of pituitary apoplexy start abruptly with (a) head­ache, (b) vomiting and (c) disturbance in consciousness, (d) visual disturbance (visual loss, eld defects or ophthalmoplegia), and (e) acute hypopituitarism [6]. Signs and symptoms associated with pituitary apoplexy may have different pro­posed pathogenesis (Box30.1).
The resulting syndrome may be mild but often presents as a catastrophic event and may be initially attributed to stroke or subarachnoid hemorrhage [2], resulting that these patients will often be seen in neurovascular reference centers—as hap­pened in the index-case, presented above.
Pituitary apoplexy was the clinical manifestation that led to the diagnosis of a pituitary lesion in more than 80% of cases [3] and in up to 97.4% of patients [4].
Box 30.1 Signs and symptoms associated with pituitary apoplexy and their proposed
pathogenesis
Headache Intrasellar contents
Nausea and vomiting
Visual eld defects
Reduced visual acuity
Reduced level of consciousness
rapidly increase in size leading to dural stretching Pain is transmitted through meningeal nerves supplying the central skull base dura
With headache and altered consciousness, nausea and vomiting can be part of intracranial hypertensive syndrome
Optic nerve, chiasm, or tract impingement by upward displacement of intrasellar contents
As a part of CNII decit syndrome can be cause by optical apparatus Displacement
With headache, nausea, and vomiting can be part of intracranial hypertensive syndrome
Sellar wall enlargement causes displacement of the superior division of the trigeminal nerve (CNV1) within the cavernous sinus
Can signal adrenal insufciency
Due to hypothalamic involvement
With vomiting and altered consciousness, the headache can be part of intracranial hypertensive syndrome that can be due to enlargement of sellar contents only, to subarachnoid hemorrhage or obstructive hydrocephalus
Can signal hypothalamic dysfunction
Due to adrenal insufciency
284
C. Martins et al.
Although headache is described as the earliest symptom [3], present in most (84–89.8%) [5, 8] or all patients [9] with apoplexy—while visual loss and ophthal­moparesis are only described in 52–57% of the patients at presentation [9, 10]—the type, localization, and severity of the headache are seldom detailed.
The literature available mentions sudden and severe headache that can be retro­orbital, bifrontal, or diffuse [3] and combined with nausea and vomiting. Apoplexy patients usually describe a signicant short duration of the headache (1–10days) than the non-apoplexy patients harboring sellar lesions (4days–30years) [5].
Cranial nerve palsy may involve III, IV, and VI, and usually signal the extension of apoplectic tumor to a specic cavernous sinus compartment [1113]. In the case of early III nerve involvement, superolateral expansion may displace the nerve, which is located horizontally in the same plane as the pituitary gland [10] and against its entry dural point (the oculomotor porus) at the cavernous sinus oculomo­tor trigone [14]. An ischemic cranial nerve syndrome can also result from compres­sion of dural arteries supplying the transdural, cavernous segments of these nerves. Because these vessels arise at the cavernous segment of the internal carotid artery and also supply the meningeal layers in the central skull base [15] a similar patho­physiology can explain the headache and ophthalmoparesis in apoplectic patients.
Hypopituitarism is usually considered when there is proof of biochemical de­ciency of at least one endocrine axis. When prolactin is elevated, a differentiation should be made between the elevation related to infundibular compression of the pituitary stalk which decreases dopamine inhibition to the pituitary gland (levels of less than 250 ng/mL) and an elevation that signals a prolactin-secreting tumor (higher than 1000ng/mL) [16].
Patients with pituitary apoplexy and low serum prolactin at presentation are deemed to have the highest intrasellar pressure and be prone to poor recovery [3] after decompressive surgery, making their management even more time pressing, explaining the expedite treatment offered to our case-example.
Secondary electrolyte abnormalities and acid–base imbalance are usually respon­sible for other life-risking ndings as arrhythmia [17], but bradycardia may result from distortion of III ventricular walls and resulting hypothalamic dysfunction.
Acute secondary adrenal insufciency is seen in approximately two-third of apo­plectic patients and can be a major source of mortality [3]. Hypocortisolemia ren­ders vasculature less responsive to pressor effects of catecholamines, which results in hemodynamic instability. It also augments vasopressin release from the posterior pituitary lobe inhibiting water excretion and resulting in dilution hyponatremia. Particularly in patients undergoing surgery and additional metabolic requirements, prompt empirical corticosteroid replacement should be undertaken, with hydrocor­tisone intravenously at rst, but orally as soon as viable and possible. If the oral route remains closed, the intramuscular route should be elected instead, because of the saturation kinetics of cortisol binding globulin [3]. Once recovered from acute stress, the hydrocortisone should be quickly tapered. For biochemically-proven insufcient-patients, a standard maintenance dose is 20–30mg per day, orally, usu­ally divided into three doses, and reevaluation of adrenocorticotropic hormone (ACTH) reserve reassessed at three months follow-up [3].